Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 trial of its lead drug for idiopathic pulmonary fibrosis (IPF) after seeing a ...

Commenting on the Champions Initiative, Cradle co-founder and chief executive Stef van Grieken said that technological ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

To avoid a tug-of-war between scientific rigour and operational efficiency, we must focus on the user and data journeys of ...

Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...

In a notice, the NIH said that indirect costs accounted for around $9 billion of its $35 billion funding spend in fiscal 2023, and the current rate has been far higher than what is allowed by other ...

The current approach to diagnosing obesity based on body mass index (BMI) is not fit for purpose as a marker for health – and by extension decisions on prescribing weight-loss therapies.

Ben Hargreaves looks into why ADHD medicines are still suffering shortages nearly a year after first being announced. The problem has emerged due to surging demand for the medication, but also ...

Adults with attention deficit hyperactivity disorder (ADHD) show large reductions in life expectancy compared to those living without that diagnosis, according to a UK study. The striking finding ...

A pioneering clinical trial backed by the EU and drugmaker Takeda will look for biomarkers that could be used to identify people at risk of developing Crohn's disease in the hope of intervening ...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven discovery.

The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at home, rather than in ...